116 related articles for article (PubMed ID: 9466357)
1. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.
Iznaga Escobar N; Morales AM; Ducongé J; Torres IC; Fernández E; Gómez JA
Nucl Med Biol; 1998 Jan; 25(1):17-23. PubMed ID: 9466357
[TBL] [Abstract][Full Text] [Related]
2. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
[TBL] [Abstract][Full Text] [Related]
4. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
[TBL] [Abstract][Full Text] [Related]
5. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3.
Morales AA; Crespo FZ; Gandolff GN; Iznaga Escobar N; Pérez NP; Hernández JC
Nucl Med Biol; 1998 Jan; 25(1):25-30. PubMed ID: 9466358
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
[TBL] [Abstract][Full Text] [Related]
10. [Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF].
Calderón Sánchez O; Zayas Crespo F; Leyva Montaña R; Beckford Vera D; Gómez JA
Rev Esp Med Nucl; 2005; 24(1):38-44. PubMed ID: 15701345
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1 and Biodistribution Study of ABT-806i, an
Gan HK; Burge M; Solomon B; Lee ST; Holen KD; Zhang Y; Ciprotti M; Lee FT; Munasinghe W; Fischer J; Ansell P; Fox G; Xiong H; Reilly EB; Humerickhouse R; Scott AM
J Nucl Med; 2021 Jun; 62(6):787-794. PubMed ID: 33509972
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor.
Vallis KA; Reilly RM; Chen P; Oza A; Hendler A; Cameron R; Hershkop M; Iznaga-Escobar N; Ramos-Suzarte M; Keane P
Nucl Med Commun; 2002 Dec; 23(12):1155-64. PubMed ID: 12464779
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody.
Schwarz SW; Connett JM; Anderson CJ; Rocque PA; Philpott GW; Guo LW; Welch MJ
Nucl Med Biol; 1994 May; 21(4):619-26. PubMed ID: 9234319
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
[TBL] [Abstract][Full Text] [Related]
17. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies.
Morales AA; Ducongé J; Alvarez-Ruiz D; Becquer-Viart ML; Núñez-Gandolff G; Fernández E; Caballero-Torres I; Iznaga-Escobar N
Nucl Med Biol; 2000 Feb; 27(2):199-206. PubMed ID: 10773550
[TBL] [Abstract][Full Text] [Related]
18. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
Kramer EL; Liebes L; Wasserheit C; Noz ME; Blank EW; Zabalegui A; Melamed J; Furmanski P; Peterson JA; Ceriani RL
Clin Cancer Res; 1998 Jul; 4(7):1679-88. PubMed ID: 9676842
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
Lam K; Chan C; Done SJ; Levine MN; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
